Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Purpose: To evaluate the efficacy and safety of robotic-arm-assisted [F]NaF-PET/CT-guided intra-articular block for lumbar facet joint (LFJ) or sacroiliac joint (SIJ) arthropathy.
Materials And Methods: In this single-centre, non-randomized, prospective phase 2 clinical-trial, participants with chronic low back pain (CLBP) were recruited from August 2022 to June 2024. Participants having NaF-avid LFJ or SIJ on [F]NaF-PET/CT underwent robotic-arm-assisted intra-articular block with steroids and local anaesthesia. Baseline, immediate post-procedural, and 3-month follow-up visual analog score (VAS), Low-Back Outcome Scale (LBOS), Oswestry Disability Index (ODI), and change in SUV values of target joints were documented. The primary end-point of the trial was ≥ 50% improvement in VAS at 3 months, and secondary end-points were improvements in ODI, LBOS by at least one grade and change in SUV. Descriptive statistics were applied. Qualitative variables were reported in percentages.
Results: Out of 85 enrolled participants, 79 (92.9%) underwent [F]NaF-PET/CT. Among them, 61 (77.2%) had NaF-avid joints, and 55(69.6%) underwent PET/CT-guided robotic-arm-assisted intra-articular blocks. The primary end-point was met in 84% (46/55) participants, and secondary end-points in 96% (53/55) and 89% (49/55), respectively. The procedure was technically successful in all the target joints. A significant change in pre- and post-procedural median SUVmax and SUVpeak of the treated joints was noticed. No major adverse effects were noticed in the participants.
Conclusion: Robotic-arm-assisted [F]NaF-PET/CT guided intra-articular blocks of LFJ and SIJ in CLBP appear to be safe and feasible in NaF-avid arthropathy. However, lack of comparison with the standard of care, small sample size, selection bias and radiation exposure limit its generalizability.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s00259-025-07516-4 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Nutritional and Pharmacological Significance of Pomegranate (Punica granatum L): A Comprehensive Narrative Review.
Nutr Rev
September 2025
Department of Pharmaceutics, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, Manipal, Karnataka 576104, India.
Pomegranate (Punica granatum L) is a rich source of bioactive compounds, including punicalagin, ellagic acid, anthocyanins, and urolithins, which contribute to its broad pharmacological potential. This review summarizes evidence from in vitro and in vivo experiments, as well as clinical studies, highlighting pomegranate's therapeutic effects in inflammation, metabolic disorders, cancer, cardiovascular disease, neurodegeneration, microbial infections, and skin conditions. Mechanistic insights show modulation of pathways such as nuclear factor-kappa B (NF-κB), mitogen-activated protein kinase (MAPK), alpha serine/threonine-protein kinase (AKT1), and nuclear factor erythroid 2-related factor 2 (Nrf2).
View Article and Find Full Text PDFLong-Term Open-Label Study Evaluating Oral Miglustat Treatment in Patients With Neuronal Ceroid Lipofuscinosis Type 3.
Neurology
October 2025
Neurology, Epilepsy and Movement Disorders Unit, Bambino Gesù Children's Hospital, IRCCS, Full Member of European Reference Network on Rare and Complex Epilepsies - EpiCARE, Rome, Italy.
Objectives: Neuronal ceroid lipofuscinosis type 3 (CLN3) is a rare lysosomal storage disorder characterized by progressive neurodegeneration. No disease-modifying treatments are currently available. Miglustat, a substrate reduction therapy, has shown preclinical efficacy in CLN3 models (conference abstract).
View Article and Find Full Text PDFOutcomes following transition from ibrutinib to zanubrutinib in patients with Waldenström macroglobulinemia from ASPEN.
Blood Adv
September 2025
Alfred Health and Monash University, East Melbourne, Australia.
Zanubrutinib is a next-generation covalent Bruton tyrosine kinase (BTK) inhibitor designed to provide complete and sustained BTK occupancy for efficacy across disease-relevant tissues, with fewer off-target adverse events (AEs) than other covalent BTK inhibitors. In the phase 3 ASPEN study (BGB-3111-302), comparable efficacy and a favorable safety profile versus ibrutinib were demonstrated in patients with MYD88-mutated Waldenström macroglobulinemia (WM), leading to approval of zanubrutinib for patients with WM. BGB-3111-LTE1 (LTE1) is a long-term extension study to which eligible patients, including patients from comparator treatment arms, could enroll following participation in various parent studies of zanubrutinib to treat B-cell malignancies.
View Article and Find Full Text PDFIntroduction: The ADHEAR is a non-surgical Bone Conduction Device (BCD) that makes use of an adhesive adapter. While clinical trials have demonstrated its efficacy with regards to audiological performance, safety and compliance, data on real-world paediatric cohorts is scarce.
Methods: This retrospective cohort study analysed data from paediatric patients fitted with ADHEAR at a tertiary centre between January 2017 and September 2024.
Pyrotinib versus Pertuzumab with Trastuzumab and Taxane in HER2-Positive Metastatic Breast Cancer: A Chinese Multicenter Real-world Study.
Oncologist
September 2025
Department of Breast Cancer Medical Oncology, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan, 410013, China.
Background: THP (trastuzumab + paclitaxel + pertuzumab) and THPy (trastuzumab + paclitaxel + pyrotinib) are widely used as first-line regimens for human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC) in China. However, direct comparative data on their efficacy and safety remain scarce. This study evaluates and compares the clinical outcomes of THPy and THP in the first-line treatment of HER2-positive MBC to guide clinical decision-making.
View Article and Find Full Text PDF